← Leaderboards
Andrew Jacob Brenner
University Of Texas Hlth Science Center
$6,506,512
Attributed
$8,523,434
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,673,941 · 5
FDA$1,849,493 · 1
By mechanism
R01$7,948,497 · 4
R21$374,464 · 1
P30$200,473 · 1
Top collaborators
- Ratna K Vadlamudi8 shared
- Stanton Furst Mchardy3 shared
- Linda A De Graffenried2 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Gangadhara R Sareddy$1,601,264
- Luiz Otavio Penalva$3,130,773
- Stanton Furst McHardy$2,435,808
- Ande Bao$548,100
- Beth A Goins$283,662
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorNovel TherapeuticsGlioblastomaPharmaceutical PreparationsClinical ResearchMalignant NeoplasmsTissuesGrowthAdultClinical DevelopmentAgonistPlayTherapeutic AgentsChemotherapyToxic EffectRadiation TherapyBrainGliomaClinical TrialsInnovationMediatingIn VitroLeadBase
Grant awards (26)
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$530,240
R01 · FY2025 · CA
Mays Cancer Center at UT Health SA$44,790
P30 · FY2025 · CA · contact PI
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$502,525
R01 · FY2024 · CA
Mays Cancer Center at UT Health SA$31,140
P30 · FY2024 · CA · contact PI
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$548,472
R01 · FY2023 · CA
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma$547,212
R01 · FY2023 · CA · contact PI
Mays Cancer Center at UT Health SA$31,140
P30 · FY2023 · CA · contact PI
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma$558,207
R01 · FY2022 · CA · contact PI
Mays Cancer Center at UT Health SA$31,140
P30 · FY2022 · CA · contact PI
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma$581,883
R01 · FY2021 · CA · contact PI
Mays Cancer Center at UT Health SA$31,140
P30 · FY2021 · CA · contact PI
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma$618,489
R01 · FY2020 · CA · contact PI
Phase 2 Study of TH-302 for the Treatment of Glioblastoma$252,191
R01 · FY2020 · FD · contact PI
Mays Cancer Center at UT Health SA$31,123
P30 · FY2020 · CA · contact PI
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma$660,911
R01 · FY2019 · CA · contact PI
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2018 · CA
Phase 2 Study of TH-302 for the Treatment of Glioblastoma$399,998
R01 · FY2017 · FD · contact PI
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2017 · CA
Omega-3 Fatty Acid Modulation of Obesity-Induced Aromatase Expression$197,701
R21 · FY2017 · CA
Phase 2 Study of TH-302 for the Treatment of Glioblastoma$399,446
R01 · FY2016 · FD · contact PI
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2016 · CA
Omega-3 Fatty Acid Modulation of Obesity-Induced Aromatase Expression$176,763
R21 · FY2016 · CA
Phase 2 Study of TH-302 for the Treatment of Glioblastoma$399,013
R01 · FY2015 · FD · contact PI
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2015 · CA
Phase 2 Study of TH-302 for the Treatment of Glioblastoma$398,845
R01 · FY2014 · FD · contact PI
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2014 · CA